Inhaled corticosteroids vs leukotriene receptor antagonists: Health care costs across varying asthma severities

Annals of Allergy, Asthma and Immunology

Volumn 97, Issue 2, 2006, Pages 236-243

  O'Connor, Richard D ^a   Parasuraman, Bhash ^b   Roberts, Craig ^c   Leibman, Christopher ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ASTRAZENECA   (United Kingdom)

^c NDC Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NEDOCROMIL; ZAFIRLUKAST;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CHILD; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG COST; DRY POWDER; EMERGENCY TREATMENT; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INFANT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAL NEBULIZER; METERED DOSE INHALER; POWDER INHALER; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TABLET FORMULATION; TREATMENT OUTCOME; UNITED STATES;

EID: 33747715791     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60020-8     Document Type: Article

References (24)

1. Mannino DM, Homa DM, Akinbami LJ, et al. Surveillance for asthma-United States, 1980-1999. MMWR Surveill Summ. 2002;51:1-13.
2. Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in the United States, 1985-1994. J Allergy Clin Immunol. 2000;106:493-499.
3. Beasley R. The burden of asthma with specific reference to the United States. J Allergy Clin Immunol. 2002;109: S482-489.
4. National Asthma Education and Prevention Program. Expert Panel Report: guidelines for the Diagnosis and Management of Asthma Update on Selected Topics-2002. J Allergy Clin Immunol. 2002;110:5141-219.
5. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health, National Heart. Lung, and Blood Institute; July 1997. Publication 97-4051.
6. Global Strategy for Asthma Management and Prevention: NHLBI/WHO Workshop report update. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 2002. Publication 02-3659.
7. Stafford RS, Ma J, Finkelstein SN, et al. National trends in asthma visits and asthma pharmacotherapy, 1978-2002. J Allergy Clin Immunol. 2003;111:729-735.
8. Ng D, Salvio F, Hicks G. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2004;CD002314.
9. Armstrong EP, Malone DC. Fluticasone is associated with lower asthma-related costs than leukotriene modifiers in a real-world analysis. Pharmacotherapy. 2002;22:1117-1123.
10. Pathak DS, Davis EA, Stanford RH. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population. Pharmacotherapy. 2002;22:166-174.
11. Orsini L, Limpa-Amara S, Crown WH, et al. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast. Ann Allergy Asthma Immunol. 2004;92:523-529.
12. Rosenbaum P, Rubin D. The central role of propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
13. Rubin DB. Estimating cuusal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757-763.
14. Ioannidis JP, Haidich AB, Lau J. Any casualties in the clash of randomised and observational evidence? BMJ. 2001;322:879-880.
15. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887-1892.
16. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878-1886.
17. Ducharme FM, Hicks GC. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2002;CD002314.
18. Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ. 2003;326:621.
19. Stempel DA, Meyer JW, Stanford RH, et al. One-year claims analysis comparing inhaled fluticasone propionate with zalirlukast for the treatment of asthma. J Allergy Clin Immunol. 2001;107:94-98.
20. Stempel DA, Mauskopf J, McLaughlin T, et al. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med. 2001;95:227-234.
21. Busse WB, Gordon RD, Galant S, et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol. 2001;107:461-468.
22. Bukstein DA, Luskin AT, Bernstein A. "Real-world" effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol. 2003;90:543-549.
23. Price DB, Ben-Joseph RH, Zhang Q. Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K. Respir Med. 2001;95:83-89.
24. Davies GM, Dasbach EJ, Santanello NC, et al. The effect of montelukast versus usual care on health care resource utilization in children aged 2 to 5 years with asthma. Clin Ther. 2004;26:1895-1904.